Safety and Efficacy of AAV9/AP4B1 For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47): A Phase 1/2 Single-Center, Open-Label Study of Stereotactic Intra-cisterna Magna Administration
Latest Information Update: 26 Oct 2025
At a glance
- Drugs BFB 101 (Primary)
- Indications Hereditary-spastic paraplegia
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors BlackfinBio
Most Recent Events
- 05 May 2025 New trial record
- 28 Apr 2025 Status changed from planning to not yet recruiting.
- 28 Apr 2025 According to a BlackfinBio media release, the trial will be conducted in the U.S. at Boston Children Hospital and is expected to commence recruiting by the end of 2025.